Physician profile

Jaime Castro

Fort Worth, TX

NPI 1932159951

$7,683.62

in general payments reported to CMS, 2019-2025

42 companies · $1,025 in 2025

The $1,025 reported for 2025 was more than what 88% of providers received nationally.

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,006.33
Education$39.66

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $1,311.80 2019-2025 Jardiance, Lyumjev, Mounjaro
Abbott Laboratories $1,066.52 2019-2025 Freestyle Libre
Abbvie INC. $622.72 2019-2025 Synthroid
Amgen INC. $529.35 2022-2025 Tepezza, Evenity, Prolia
Novo Nordisk INC $522.85 2020-2025 Ozempic, Rybelsus, Wegovy
Sanofi-Aventis U.S. LLC $385.51 2019-2025
Medtronic Minimed, INC. $329.36 2019-2020
Xeris Pharmaceuticals, INC. $321.21 2020-2025 Recorlev, Gvoke Hypopen
Medtronic, INC. $280.39 2021-2025 Minimed 780g, Minimed 770g, Inceptiv
Astrazeneca Pharmaceuticals LP $213.31 2019-2021
Dexcom, INC. $171.41 2021-2025 Dexcom G6 Transmitter
Chiesi USA, INC. $168.00 2024 Mycapssa
Pfizer INC. $159.80 2021-2024
Tandem Diabetes Care, INC. $110.69 2019-2024 T:Slim X2 Insulin Pump With Control-Iq
Insulet Corporation $108.21 2019-2024 Omnipod
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $101.16 2019-2021
Zealand Pharma US, INC. $100.78 2021-2022
Corcept Therapeutics $98.28 2020-2024 Korlym
Medicure Pharma INC. $94.88 2020
Madrigal Pharmaceuticals $93.71 2025 Rezdiffra
Bayer Healthcare Pharmaceuticals INC. $90.86 2020-2024
Horizon Therapeutics Plc $84.58 2021-2023 Tepezza
Ibsa Pharma INC. $81.31 2019-2023 Tirosint, Licart
Novartis Pharmaceuticals Corporation $59.43 2024-2025
Shire North American Group INC $50.77 2019
Globus Medical, INC. $50.01 2025 Senza
Recordati_rare_diseases_inc. $49.49 2023 Signifor Lar, Isturisa
Janssen Pharmaceuticals, INC $48.39 2019-2020
Glaxosmithkline, LLC. $48.08 2025 Shingrix, Arexvy
Sequel Med Tech, LLC $45.79 2025 Twiist
Mannkind Corporation $41.39 2023 Afrezza
Boehringer Ingelheim Pharmaceuticals, INC. $40.02 2021-2023 Jardiance
Nevro Corp. $34.85 2022
Intra-Sana Laboratories $22.81 2025 Glycate, Reltone 400 Mg, Reltone 200 Mg
Ultragenyx Pharmaceutical INC. $21.65 2022
Grt US Holding, INC. $21.41 2021
Roche Diabetes Care, INC. $21.16 2020
Antares Pharma, INC. $18.85 2022
Optos, INC. $18.51 2020
Radius Health, INC. $16.82 2025 Tymlos
Sun Pharmaceutical Industries INC. $13.96 2021
Companion Medical, INC. $13.54 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$126.02 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jaime Castro

$7,683.62

in general payments reported 2019-2025

Years
2019-2025
Top company
Lilly USA, LLC
Context
The $1,025 reported for 2025 was more than what 88% of providers received nationally.

https://glasscript.com/doctor/359688/jaime-castro

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.